Pazopanib for Treating Uterine Leiomyosarcoma

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to test any good and bad effects of the study drug pazopanib.

n/a

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

See also
Status	Clinical Trial	Phase
Completed	`NCT00390234` - Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma	Phase 2
Completed	`NCT00245102` - Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma	Phase 2
Completed	`NCT00378911` - Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus	Phase 2
Recruiting	`NCT05649956` - Letrozole in Uterine Leiomyosarcoma	Phase 2
Active, not recruiting	`NCT06244251` - Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids	N/A
Recruiting	`NCT04727242` - CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma	Phase 2
Completed	`NCT00659360` - AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma	Phase 2
Completed	`NCT00614835` - Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus	N/A